COUR Pharma

An excellent time enjoying the Chicago skyline with our incredible team at COUR!

COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced that the first patient has been dosed in the Company’s first-in-human proof-of-concept (Phase 1b/2a) of its lead candidate, CNP-201, for the treatment of peanut allergy.

HOME | Courpeanuttrial Chicago, Ill. (January 8th, 2022) – COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced that the first patient has been dosed in the Company’s first-in-human proof-of-concept (Phase 1b/2a) of its lead can...

COUR’s intracellular T-cell reprograming leads to a reduction to anti-drug and neutralizing antibodies.

www.frontiersin.org

Congratulations to the team at COUR for driving innovation in Celiac Disease!

"TAK-101 was well tolerated and prevented gluten-induced immune activation in Celiac Disease. The findings from the present clinical trial suggest that antigen-specific tolerance was induced and represent a novel approach translatable to other immune-mediated diseases"

TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study In celiac disease (CeD), gluten induces immune activation, leading to enteropathy. TAK-101, gluten protein (gliadin) encapsulated in negatively charged poly(dl-lactide-co-glycolic acid) nanoparticles, is designed to induce gluten-specific tolerance.